Compare KWR & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | CLDX |
|---|---|---|
| Founded | 1918 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1994 | 1995 |
| Metric | KWR | CLDX |
|---|---|---|
| Price | $119.92 | $28.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $152.50 | $44.50 |
| AVG Volume (30 Days) | 158.7K | ★ 857.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,888,634,000.00 | $12,743,000.00 |
| Revenue This Year | $5.05 | $97.61 |
| Revenue Next Year | $4.03 | $252.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.66 | ★ 87.78 |
| 52 Week Low | $95.91 | $14.40 |
| 52 Week High | $183.01 | $31.85 |
| Indicator | KWR | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 23.40 | 51.12 |
| Support Level | $111.56 | $24.70 |
| Resistance Level | $126.57 | $30.90 |
| Average True Range (ATR) | 5.23 | 1.22 |
| MACD | -2.21 | -0.14 |
| Stochastic Oscillator | 10.03 | 1.88 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.